Attached files
file | filename |
---|---|
EX-99.1 - EXHIBIT 99.1 - IMMUNE PHARMACEUTICALS INC | tv485285_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 7, 2018
IMMUNE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-36602 | 52-1841431 |
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
550 Sylvan Avenue, Suite 101, Englewood Cliffs, NJ | 07632 |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (201) 464-2677
(Former name or former address, if changed since last report) N/A
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company | ¨ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | ¨ |
Item 8.01 | Other Events |
The Company announced today that the Disciplinary Board of Nasdaq Stockholm has decided to delist the Company's shares on such Swedish exchange. Trading of the Company's shares on Nasdaq First North will be discontinued on March 29, 2018. The delisting does not affect the Company's trading status on the Nasdaq Capital Market in the United States.
The Nasdaq First North Disciplinary Board acknowledged that the Company has recently taken measures to insure compliance; however, these measures are insufficient to rectify the prior breaches of the Rule Book.
The Company intends to investigate alternate arrangements to accommodate its shareholders who trade the Company's stock on Nasdaq First North Stockholm.
A copy of the Company’s press release regarding the above-described item is attached as Exhibit 99.1, is incorporated by reference herein and is filed as part of this Current Report on Form 8-K.
Item 9.01 | Financial Statements and Exhibits |
(d) | Exhibits |
Exhibit Number | Description |
99.1 | Press Release, dated February 8, 2018 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
IMMUNE PHARMACEUTICALS INC. | |||
By: | /s/ Elliot M. Maza | ||
Name: | Elliot M. Maza | ||
Title: | President and Chief Executive Officer | ||
Date: February 8, 2018 |